BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

349 related articles for article (PubMed ID: 34332450)

  • 21. Trastuzumab-monomethyl auristatin E conjugate exhibits potent cytotoxic activity in vitro against HER2-positive human breast cancer.
    Abdollahpour-Alitappeh M; Lotfinia M; Bagheri N; Sineh Sepehr K; Habibi-Anbouhi M; Kobarfard F; Balalaie S; Foroumadi A; Abbaszadeh-Goudarzi G; Abbaszadeh-Goudarzi K; Abolhassani M
    J Cell Physiol; 2019 Mar; 234(3):2693-2704. PubMed ID: 30246298
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Conjugating MMAE to a novel anti-HER2 antibody for selective targeted delivery.
    Li L; Xu MZ; Wang L; Jiang J; Dong LH; Chen F; Dong K; Song HF
    Eur Rev Med Pharmacol Sci; 2020 Dec; 24(24):12929-12937. PubMed ID: 33378043
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A Novel Anti-CD22 Anthracycline-Based Antibody-Drug Conjugate (ADC) That Overcomes Resistance to Auristatin-Based ADCs.
    Yu SF; Zheng B; Go M; Lau J; Spencer S; Raab H; Soriano R; Jhunjhunwala S; Cohen R; Caruso M; Polakis P; Flygare J; Polson AG
    Clin Cancer Res; 2015 Jul; 21(14):3298-306. PubMed ID: 25840969
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Glypican-1 Promotes Tumorigenesis by Regulating the PTEN/Akt/β-Catenin Signaling Pathway in Esophageal Squamous Cell Carcinoma.
    Li J; Chen Y; Zhan C; Zhu J; Weng S; Dong L; Liu T; Shen X
    Dig Dis Sci; 2019 Jun; 64(6):1493-1502. PubMed ID: 30730015
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A novel complement-fixing IgM antibody targeting GPC1 as a useful immunotherapeutic strategy for the treatment of pancreatic ductal adenocarcinoma.
    Busato D; Capolla S; Durigutto P; Mossenta M; Bozzer S; Sblattero D; Macor P; Dal Bo M; Toffoli G
    J Transl Med; 2023 Nov; 21(1):864. PubMed ID: 38017492
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Preclinical Efficacy of the Antibody-Drug Conjugate CLDN6-23-ADC for the Treatment of CLDN6-Positive Solid Tumors.
    McDermott MSJ; O'Brien NA; Hoffstrom B; Gong K; Lu M; Zhang J; Luo T; Liang M; Jia W; Hong JJ; Chau K; Davenport S; Xie B; Press MF; Panayiotou R; Handly-Santana A; Brugge JS; Presta L; Glaspy J; Slamon DJ
    Clin Cancer Res; 2023 Jun; 29(11):2131-2143. PubMed ID: 36884217
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Oridonin-loaded and GPC1-targeted gold nanoparticles for multimodal imaging and therapy in pancreatic cancer.
    Qiu W; Chen R; Chen X; Zhang H; Song L; Cui W; Zhang J; Ye D; Zhang Y; Wang Z
    Int J Nanomedicine; 2018; 13():6809-6827. PubMed ID: 30425490
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sacituzumab govitecan, an antibody-drug conjugate targeting trophoblast cell-surface antigen 2, shows cytotoxic activity against poorly differentiated endometrial adenocarcinomas in vitro and in vivo.
    Perrone E; Manara P; Lopez S; Bellone S; Bonazzoli E; Manzano A; Zammataro L; Bianchi A; Zeybek B; Buza N; Tymon-Rosario J; Altwerger G; Han C; Menderes G; Huang GS; Ratner E; Silasi DA; Azodi M; Hui P; Schwartz PE; Scambia G; Santin AD
    Mol Oncol; 2020 Mar; 14(3):645-656. PubMed ID: 31891442
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Excellent effects and possible mechanisms of action of a new antibody-drug conjugate against EGFR-positive triple-negative breast cancer.
    Zhou DD; Bai WQ; Zhai XT; Sun LP; Zhen YS; Li ZR; Miao QF
    Mil Med Res; 2021 Dec; 8(1):63. PubMed ID: 34879870
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In vivo drug-linker stability of an anti-CD30 dipeptide-linked auristatin immunoconjugate.
    Sanderson RJ; Hering MA; James SF; Sun MM; Doronina SO; Siadak AW; Senter PD; Wahl AF
    Clin Cancer Res; 2005 Jan; 11(2 Pt 1):843-52. PubMed ID: 15701875
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Activating Autophagy Enhanced the Antitumor Effect of Antibody Drug Conjugates Rituximab-Monomethyl Auristatin E.
    Wang Y; Zhang X; Fan J; Chen W; Luan J; Nan Y; Wang S; Chen Q; Zhang Y; Wu Y; Ju D
    Front Immunol; 2018; 9():1799. PubMed ID: 30123222
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Therapeutic potential of amanitin-conjugated anti-epithelial cell adhesion molecule monoclonal antibody against pancreatic carcinoma.
    Moldenhauer G; Salnikov AV; Lüttgau S; Herr I; Anderl J; Faulstich H
    J Natl Cancer Inst; 2012 Apr; 104(8):622-34. PubMed ID: 22457476
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Quantitative Evaluation of the Effect of Antigen Expression Level on Antibody-Drug Conjugate Exposure in Solid Tumor.
    Bussing D; Sharma S; Li Z; Meyer LF; Shah DK
    AAPS J; 2021 Apr; 23(3):56. PubMed ID: 33856579
    [TBL] [Abstract][Full Text] [Related]  

  • 34. HER2-targeted antibody drug conjugates for ovarian cancer therapy.
    Jiang J; Dong L; Wang L; Wang L; Zhang J; Chen F; Zhang X; Huang M; Li S; Ma W; Xu Q; Huang C; Fang J; Wang C
    Eur J Pharm Sci; 2016 Oct; 93():274-86. PubMed ID: 27509865
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A novel humanized anti-HER2 antibody conjugated with MMAE exerts potent anti-tumor activity.
    Yao X; Jiang J; Wang X; Huang C; Li D; Xie K; Xu Q; Li H; Li Z; Lou L; Fang J
    Breast Cancer Res Treat; 2015 Aug; 153(1):123-33. PubMed ID: 26253944
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Therapeutic effect of a MUC1-specific monoclonal antibody-drug conjugates against pancreatic cancer model.
    Wu G; Li L; Liu M; Chen C; Wang G; Jiang Z; Qin Y; He L; Li H; Cao J; Gu H
    Cancer Cell Int; 2022 Dec; 22(1):417. PubMed ID: 36572921
    [TBL] [Abstract][Full Text] [Related]  

  • 37. DCDT2980S, an anti-CD22-monomethyl auristatin E antibody-drug conjugate, is a potential treatment for non-Hodgkin lymphoma.
    Li D; Poon KA; Yu SF; Dere R; Go M; Lau J; Zheng B; Elkins K; Danilenko D; Kozak KR; Chan P; Chuh J; Shi X; Nazzal D; Fuh F; McBride J; Ramakrishnan V; de Tute R; Rawstron A; Jack AS; Deng R; Chu YW; Dornan D; Williams M; Ho W; Ebens A; Prabhu S; Polson AG
    Mol Cancer Ther; 2013 Jul; 12(7):1255-65. PubMed ID: 23598530
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sacituzumab Govitecan (IMMU-132), an Anti-Trop-2/SN-38 Antibody-Drug Conjugate: Characterization and Efficacy in Pancreatic, Gastric, and Other Cancers.
    Cardillo TM; Govindan SV; Sharkey RM; Trisal P; Arrojo R; Liu D; Rossi EA; Chang CH; Goldenberg DM
    Bioconjug Chem; 2015 May; 26(5):919-31. PubMed ID: 25915780
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Characterization of Site-Specifically Conjugated Monomethyl Auristatin E- and Duocarmycin-Based Anti-PSMA Antibody-Drug Conjugates for Treatment of PSMA-Expressing Tumors.
    Lütje S; Gerrits D; Molkenboer-Kuenen JD; Herrmann K; Fracasso G; Colombatti M; Boerman OC; Heskamp S
    J Nucl Med; 2018 Mar; 59(3):494-501. PubMed ID: 29146698
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Development and Properties of Valine-Alanine based Antibody-Drug Conjugates with Monomethyl Auristatin E as the Potent Payload.
    Wang Y; Fan S; Zhong W; Zhou X; Li S
    Int J Mol Sci; 2017 Aug; 18(9):. PubMed ID: 28841157
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.